r-n-jРоссийский неврологический журналRussian neurological journal2658-79472686-7192МИА10.30629/2658-7947-2022-27-3-5-10r-n-j-315Research ArticleОБЗОРЫREVIEWSГепанты для купирования приступов мигрениRelief of migraine attack — hepantsЯдгаровИ. С.YadgarovI. S.

Андижан

Andijan

iosifyadgarov@yahoo.comhttps://orcid.org/0000-0001-9978-4180ФилатоваЕ. Г.FilatovaE. G.

Филатова Елена Глебовна —  

Москва

Moscow

eg-filatova@mail.ruhttps://orcid.org/0000-0003-0842-8557ГолубевВ. Л.GolubevV. L.

Москва

Moscow

vgol_59@mail.ruhttps://orcid.org/0000-0002-4447-2152БердниковаА. В.BerdnikovaA. V.

Москва

Moscow

asimcin@mail.ruАндижанский государственный медицинский институтУзбекистанAndijan State Medical InstituteUzbekistanПервый Московский государственный медицинский университет им. И.М. Сеченова МЗ РФ (Сеченовский Университет)РоссияI.M. Sechenov First Moscow Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation202213072022273510Copyright © Ядгаров И.С., Филатова Е.Г., Голубев В.Л., Бердникова А.В., 20222022Ядгаров И.С., Филатова Е.Г., Голубев В.Л., Бердникова А.В.Yadgarov I.S., Filatova E.G., Golubev V.L., Berdnikova A.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.r-n-j.com/jour/article/view/315

В обзоре представлен механизм действия нового класса таргетных препаратов для лечения мигрени антагонистами рецепторов кальцитонин-ген-родственного пептида — гепантов. В настоящее время два препарата — уброгепант и римегепант — одобрены в США для купирования острых приступов мигрени. В РФ пока ни один из препаратов этого нового класса не зарегистрирован, однако это возможно в ближайшем будущем. Приведены результаты рандомизированных клинических исследований, продемонстрировавшие их эффективность по сравнению с триптанами и плацебо, а также хорошую переносимость и безопасность. Римегепант и уброгепант вызывают минимальные нежелательные эффекты и безопасны для людей с сердечно-сосудистыми заболеваниями. Гепанты могут представлять альтернативу для пациентов с мигренью, которые не могут применять триптаны из-за плохой их переносимости.

Thе review presents the mechanism of action of a new class of targeted drugs for the treatment of migraine with CGRP gepant receptor antagonists — gepants. Currently, two drugs — ubrogepant and rimegepant are approved by the FDA for the relief of acute migraine attacks in the United States. In the Russian Federation, none of the drugs of this new class is registered, however, this is possible in the near future. The review presents the results of RCTs that demonstrated their effectiveness in comparison with triptans and placebo, as well as good tolerability and safety. Rimegepant and ubrogepant cause minimal side effects and are safe for people with cardiovascular diseases. Gepants may provide an alternative for migraine patients who do not tolerate the side effects observed with triptans, as well as the main therapy.

мигреньприступ мигренилечение приступа мигренигепантыmigraineacute migraine attacktreatment of migraine attackgepantsReferencesКопишинская С.В., Густов А.В. Генетические аспекты мигрени. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(7):124–129. [Kopishinskaja S.V., Gustov A.V. Genetic aspects of migraine. Journal of Neurology and Psychiatry. 2015;115(7):124–129. (In Russ.)]. https://doi.org/10.17116/jnevro201511571124-129Копишинская С.В., Густов А.В. Генетические аспекты мигрени. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(7):124–129. [Kopishinskaja S.V., Gustov A.V. Genetic aspects of migraine. Journal of Neurology and Psychiatry. 2015;115(7):124–129. (In Russ.)]. https://doi.org/10.17116/jnevro201511571124-129Табеева Г.Р. Головная боль. Руководство для врачей. М.: Гэотар-медиа, 2018. [Tabeeva G.R. Headache. Guideline for doctors. M.: Geotar-media, 2018. (In Russ.)]. http://catalog.geotar.ru/lots/NF0009525.htmlТабеева Г.Р. Головная боль. Руководство для врачей. М.: Гэотар-медиа, 2018. [Tabeeva G.R. Headache. Guideline for doctors. M.: Geotar-media, 2018. (In Russ.)]. http://catalog.geotar.ru/lots/NF0009525.htmlHamelsky S., Stewart F., Lipton R. Epidemiology of migraine. Curr Pain Headache Rep. 2001;5:189–194. https://doi.org/10.1007/s11916-001-0088-9Hamelsky S., Stewart F., Lipton R. Epidemiology of migraine. Curr Pain Headache Rep. 2001;5:189–194. https://doi.org/10.1007/s11916-001-0088-9Lipton R., Bigal M. The epidemiology of migraine. Am J Med. 2005;118(1):3–10. https://doi.org/10.1016/j.amjmed.2005.01.014Lipton R., Bigal M. The epidemiology of migraine. Am J Med. 2005;118(1):3–10. https://doi.org/10.1016/j.amjmed.2005.01.014GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and causespecific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171. https://doi.org/10.1016/S0140-6736(14)61682-2GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and causespecific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171. https://doi.org/10.1016/S0140-6736(14)61682-2Viana M., Sances G., Linde M., Ghiotto N., Guaschino E., Allena M., Terrazzino S., Nappi G., Goadsby J., Tassorelli C. Clinical features of migraine aura: result from a prospective diaryaided study. Cephalalgia. 2017;37(10):979–989. https://doi.org/10.1177/0333102416657147Viana M., Sances G., Linde M., Ghiotto N., Guaschino E., Allena M., Terrazzino S., Nappi G., Goadsby J., Tassorelli C. Clinical features of migraine aura: result from a prospective diaryaided study. Cephalalgia. 2017;37(10):979–989. https://doi.org/10.1177/0333102416657147Gajria K., Lee L.K., Flores N.M., Aycardi E., Gandhi S.K. Humanistic and economic burden of nausea and vomiting among migraine sufferers. J Pain Res. 2017;10:689–698. https://doi.org/10.2147/JPR.S124683Gajria K., Lee L.K., Flores N.M., Aycardi E., Gandhi S.K. Humanistic and economic burden of nausea and vomiting among migraine sufferers. J Pain Res. 2017;10:689–698. https://doi.org/10.2147/JPR.S124683Ferrari M.D., Goadsby P.J., Roon K.I., Lipton R.B. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–658. https://doi.org/10.1046/j.1468-2982.2002.00404.xFerrari M.D., Goadsby P.J., Roon K.I., Lipton R.B. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–658. https://doi.org/10.1046/j.1468-2982.2002.00404.xGeraud G., Keywood C., Senard J.M. Migraine headache recurrence:relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376– 388. https://doi.org/10.1046/j.1526-4610.2003.03073.xGeraud G., Keywood C., Senard J.M. Migraine headache recurrence:relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376– 388. https://doi.org/10.1046/j.1526-4610.2003.03073.xNegro A., Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12(6):593–601. https://doi:10.1007/s10194-011-0388-3Negro A., Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12(6):593–601. https://doi:10.1007/s10194-011-0388-3Hong P., Tan T., Liu Y., Xiao J. Gepants for abortive treatment of migraine: A network meta-analysis. Brain Behav. 2020;10(8):e01701. https://doi.org/10.1002/brb3.1701Hong P., Tan T., Liu Y., Xiao J. Gepants for abortive treatment of migraine: A network meta-analysis. Brain Behav. 2020;10(8):e01701. https://doi.org/10.1002/brb3.1701Villalon C.M., Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009,124(3):309– 322. https://doi.org/10.1016/j.pharmthera.2009.09.003Villalon C.M., Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009,124(3):309– 322. https://doi.org/10.1016/j.pharmthera.2009.09.003Edvinsson L., Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366–373. https://doi.org/10.1177/0333102417736900.Edvinsson L., Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366–373. https://doi.org/10.1177/0333102417736900.Noseda R., Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013;154(1):44–53. https://doi.org/10.1016/j.pain.2013.07.021Noseda R., Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013;154(1):44–53. https://doi.org/10.1016/j.pain.2013.07.021Азимова Ю.Э. Мигрень: современный взгляд на классификацию, патофизиологию и терапию. Медицинcкий совет. 2014;5:27–31. [Azimova Y.E. Migraine: modern view of the classification, pathophysiology and specific therapy. Medical Council. 2014;5:27–31. (In Russ.)]. https://doi.org/10.21518/2079-701X-2014-5-27-29Азимова Ю.Э. Мигрень: современный взгляд на классификацию, патофизиологию и терапию. Медицинcкий совет. 2014;5:27–31. [Azimova Y.E. Migraine: modern view of the classification, pathophysiology and specific therapy. Medical Council. 2014;5:27–31. (In Russ.)]. https://doi.org/10.21518/2079-701X-2014-5-27-29Pan K.S., Siow A., Hay D.L., Walker C.S. Antagonism of CGRP Signaling by Rimegepant at Two Receptors. Front Pharmacol. 2020;11:1240. https://doi.org/10.3389/fphar.2020.01240Pan K.S., Siow A., Hay D.L., Walker C.S. Antagonism of CGRP Signaling by Rimegepant at Two Receptors. Front Pharmacol. 2020;11:1240. https://doi.org/10.3389/fphar.2020.01240Goadsby P.J., Holland P.R., Martins-Oliveira M., Hoffmann J., Schankin C., Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. https://doi.org/10.1152/physrev.00034.2015Goadsby P.J., Holland P.R., Martins-Oliveira M., Hoffmann J., Schankin C., Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. https://doi.org/10.1152/physrev.00034.2015Дубенко О.Е. Кальцитонин-ген-связанный пептид при мигрени: патогенетический фактор и терапевтическая мишень (обзор). Международный неврологический журнал. 2018;2(96):71–77. [Dubenko O.E. Calcitonin gene-related peptide: pathogenetic factor and therapeutic target (review). International Neurological Journal. 2018;2(96):71–77. (In Russ.)]. http://dx.doi.org/10.22141/2224-0713.2.96.2018.130481Дубенко О.Е. Кальцитонин-ген-связанный пептид при мигрени: патогенетический фактор и терапевтическая мишень (обзор). Международный неврологический журнал. 2018;2(96):71–77. [Dubenko O.E. Calcitonin gene-related peptide: pathogenetic factor and therapeutic target (review). International Neurological Journal. 2018;2(96):71–77. (In Russ.)]. http://dx.doi.org/10.22141/2224-0713.2.96.2018.130481Kaiser E.A., Russo A.F. CGRP and migraine: could PACAP play a role too? Neuropeptides. 2013;47(6):451–461. https://doi.org/10.1016/j.npep.2013.10.010Kaiser E.A., Russo A.F. CGRP and migraine: could PACAP play a role too? Neuropeptides. 2013;47(6):451–461. https://doi.org/10.1016/j.npep.2013.10.010Burstein R., Noseda R., Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619– 6629. https://doi.org/10.1523/JNEUROSCI.0373-15.2015Burstein R., Noseda R., Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619– 6629. https://doi.org/10.1523/JNEUROSCI.0373-15.2015Negro A., Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555–567. https://doi.org/10.1080/13543784.2019.1618830Negro A., Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555–567. https://doi.org/10.1080/13543784.2019.1618830Loder E., Tfelt-Hansen P. The emperor’s new gepants: are the effects of the new oral CGRP antagonists clinically meaningful? Headache. 2019;59(1):113–117. https://doi.org/10.1111/head.13444Loder E., Tfelt-Hansen P. The emperor’s new gepants: are the effects of the new oral CGRP antagonists clinically meaningful? Headache. 2019;59(1):113–117. https://doi.org/10.1111/head.13444Koulchitsky S., Fischer M.J.M., Messlinger K. Calcitonin generelated peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia. 2009;29(4):408–417. https://doi.org/10.1111/j.1468-2982.2008.01745.xKoulchitsky S., Fischer M.J.M., Messlinger K. Calcitonin generelated peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia. 2009;29(4):408–417. https://doi.org/10.1111/j.1468-2982.2008.01745.xFischer M.J.M., Koulchitsky S., Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci. 2005;25(25):5877–5883. https://doi.org/10.1523/JNEUROSCI.0869-05.2005Fischer M.J.M., Koulchitsky S., Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci. 2005;25(25):5877–5883. https://doi.org/10.1523/JNEUROSCI.0869-05.2005Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., Eberlein W. Pharmacological profile of BIBN4096BS,the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129(3):420–423. https://doi.org/10.1038/sj.bjp.0703110Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., Eberlein W. Pharmacological profile of BIBN4096BS,the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129(3):420–423. https://doi.org/10.1038/sj.bjp.0703110Conway C.M., Croop R., Dubowchik G.M., Coric V., Lipton R.B. Cardiovascular safety of rimegepant 75 mg in 3 randomized clinical trials and systematic evaluations from in vitro, ex vivo and in vivo nonclinical assays. Neurology. 2020;94(15Supplement):2141. https://n.neurology.org/content/94/15_Supplement/2141Conway C.M., Croop R., Dubowchik G.M., Coric V., Lipton R.B. Cardiovascular safety of rimegepant 75 mg in 3 randomized clinical trials and systematic evaluations from in vitro, ex vivo and in vivo nonclinical assays. Neurology. 2020;94(15Supplement):2141. https://n.neurology.org/content/94/15_Supplement/2141Dodick D., Lipton R., Ailani J., Simgh R., Shewale A., Yu S., Viswanathan H. Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II. Headache. 2020;60(4):686–700. https://doi.org/10.1111/head.13766Dodick D., Lipton R., Ailani J., Simgh R., Shewale A., Yu S., Viswanathan H. Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II. Headache. 2020;60(4):686–700. https://doi.org/10.1111/head.13766Voss T., Lipton R., Dodick D., Dupre N., Ge J., Assaid C., Aurora S., Mishelson D. A phase IIb randomized, doubleblind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–898. https://doi.org/10.1177/0333102416653233Voss T., Lipton R., Dodick D., Dupre N., Ge J., Assaid C., Aurora S., Mishelson D. A phase IIb randomized, doubleblind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–898. https://doi.org/10.1177/0333102416653233Storer R.J., Akerman S., Goadsby P.J. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;42(7):1171–1181. https://doi.org/10.1038/sj.bjp.0705807Storer R.J., Akerman S., Goadsby P.J. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;42(7):1171–1181. https://doi.org/10.1038/sj.bjp.0705807Xu F., Sun W.Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine. Front Pharmacol. 2019;10:795. https://doi.org/10.3389/ fphar.2019.00795Xu F., Sun W.Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine. Front Pharmacol. 2019;10:795. https://doi.org/10.3389/ fphar.2019.00795Moreno-Ajona D., Perez-Rodriguez A., Goadsby P.J. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33(3):309–315. https://doi.org/10.1097/WCO.0000000000000806Moreno-Ajona D., Perez-Rodriguez A., Goadsby P.J. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33(3):309–315. https://doi.org/10.1097/WCO.0000000000000806Moreno-Ajona D., Perez-Rodriguez A., Goadsby P.J. Smallmolecule CGRP receptor antagonists. A new approach to the acute and preventive treatment of migraine. Med Drug Discov. 2020;7,100053. https://doi.org/10.1016/j.medidd.2020.100053Moreno-Ajona D., Perez-Rodriguez A., Goadsby P.J. Smallmolecule CGRP receptor antagonists. A new approach to the acute and preventive treatment of migraine. Med Drug Discov. 2020;7,100053. https://doi.org/10.1016/j.medidd.2020.100053Chan T.L.H., Cowan R.P., Woldeamanuel Y.W. Calcitonin GeneRelated Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis. Headache. 2020;60(7):1489–1499. https://doi.org/10.1111/head.13858Chan T.L.H., Cowan R.P., Woldeamanuel Y.W. Calcitonin GeneRelated Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis. Headache. 2020;60(7):1489–1499. https://doi.org/10.1111/head.13858Ailani J., Lipton R.B., Hutchinson S., Knievel K., Lu K., Butler M., Yu S.Y., Finnegan M., Severt L., Trugman J.M. LongTerm Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Headache. 2020;60(1):141–152. https://doi.org/10.1111/head.13682Ailani J., Lipton R.B., Hutchinson S., Knievel K., Lu K., Butler M., Yu S.Y., Finnegan M., Severt L., Trugman J.M. LongTerm Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Headache. 2020;60(1):141–152. https://doi.org/10.1111/head.13682Dodick D.W., Goadsby P.J., Lakkis H.,Lu K., Jakate A., Finegan M., Szegedi A., Trugman J.M. Ubrogepant Achieves onset of pain relief at 1 hour for the acute treatment of migraine. Headache. 2019;59(s1):P103. https://doi.org/10.1111/head.13549Dodick D.W., Goadsby P.J., Lakkis H.,Lu K., Jakate A., Finegan M., Szegedi A., Trugman J.M. Ubrogepant Achieves onset of pain relief at 1 hour for the acute treatment of migraine. Headache. 2019;59(s1):P103. https://doi.org/10.1111/head.13549Jakate A., Boinpally R., Butler M., Lu K., Womack K., McGeeney D., Periclou A. Singlе therapeutic doses of ubrogepant are not associated with a clinically relevant drug-drug interaction when co-administered with acetaminophen or naproxen. Headache. 2019;59(s1):P96. https://doi.org/10.1111/head.13549Jakate A., Boinpally R., Butler M., Lu K., Womack K., McGeeney D., Periclou A. Singlе therapeutic doses of ubrogepant are not associated with a clinically relevant drug-drug interaction when co-administered with acetaminophen or naproxen. Headache. 2019;59(s1):P96. https://doi.org/10.1111/head.13549Curto M., Capi M., Cipolla F., Cisale G Y., Martelletti P., Lionetto L. Ubrogepant for the treatment of migraine. Expert Opinion Pharmacother. 2020;21(7):755–759. https://doi.org/10.1080/14656566.2020.1721462Curto M., Capi M., Cipolla F., Cisale G Y., Martelletti P., Lionetto L. Ubrogepant for the treatment of migraine. Expert Opinion Pharmacother. 2020;21(7):755–759. https://doi.org/10.1080/14656566.2020.1721462Marcus R., Goadsby P.J., Dodick D., Stock D., Manos G., Fischer T.Z. BMS- 927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, doseranging trial. Cephalalgia. 2014;34(2):114–125. https://doi.org/10.1177/0333102413500727Marcus R., Goadsby P.J., Dodick D., Stock D., Manos G., Fischer T.Z. BMS- 927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, doseranging trial. Cephalalgia. 2014;34(2):114–125. https://doi.org/10.1177/0333102413500727Croop R., Goadsby P.J., Stock D.A., Conway C.M., Forshaw M., Stock E.G., Coricc V., Lipton R.B. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebocontrolled trial. Lancet. 2019;394(10200):737–745. https://doi.org/10.1016/S0140-6736(19)31606-XCroop R., Goadsby P.J., Stock D.A., Conway C.M., Forshaw M., Stock E.G., Coricc V., Lipton R.B. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebocontrolled trial. Lancet. 2019;394(10200):737–745. https://doi.org/10.1016/S0140-6736(19)31606-XJohnston K., Popoff E., Deighton A., Dabirvaziri P., Harris L., Thiry A., Croop R., Coric V., L’Italien G., Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Res. 2021;2:1–12. https://doi.org/10.1080/14737167.2021.1945444Johnston K., Popoff E., Deighton A., Dabirvaziri P., Harris L., Thiry A., Croop R., Coric V., L’Italien G., Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Res. 2021;2:1–12. https://doi.org/10.1080/14737167.2021.1945444Peters G.L., Hennessey E.K. Rimegepant: acute treatment for migraine headaches. Pain Manag. 2021;11(3):259–266. https://doi.org/10.2217/pmt-2020-0090Peters G.L., Hennessey E.K. Rimegepant: acute treatment for migraine headaches. Pain Manag. 2021;11(3):259–266. https://doi.org/10.2217/pmt-2020-0090Gao B., Yang Y., Wang Z., Sun Y, Chen Z., Zhu Y., Wang Z. Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials. Front Pharmacol. 2020;10:1577. https://doi.org/10.3389/fphar.2019.01577Gao B., Yang Y., Wang Z., Sun Y, Chen Z., Zhu Y., Wang Z. Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials. Front Pharmacol. 2020;10:1577. https://doi.org/10.3389/fphar.2019.01577Lipton R.B., Croop R., Stock E.G., Stock D.A., Morris B.A., Frost M., Dubowchik G.M., Conway C.M., Coric V., Goadsby P.J. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142–149. https://doi.org/10.1056/NEJMoa1811090Lipton R.B., Croop R., Stock E.G., Stock D.A., Morris B.A., Frost M., Dubowchik G.M., Conway C.M., Coric V., Goadsby P.J. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142–149. https://doi.org/10.1056/NEJMoa1811090Hutchinson S., Schim J., Lipton R., ThiryA., Morris B., Coric V., Croop R. Safety of Rimegepant 75mg in adults with migraine: no effects of age, sex, or race in 3 phase 3 trials. Headache. 2019;59(s1):P247LB. https://doi.org/10.1111/head.13549Hutchinson S., Schim J., Lipton R., ThiryA., Morris B., Coric V., Croop R. Safety of Rimegepant 75mg in adults with migraine: no effects of age, sex, or race in 3 phase 3 trials. Headache. 2019;59(s1):P247LB. https://doi.org/10.1111/head.13549Edvinsson L. Rimegepant oral disintegrating tablet for migraine. Lancet. 2019;394(10200):711–712. https://doi.org/10.1016/s0140-6736(19)31611-3Edvinsson L. Rimegepant oral disintegrating tablet for migraine. Lancet. 2019;394(10200):711–712. https://doi.org/10.1016/s0140-6736(19)31611-3Rimegepant (Nurtec ODT) for acute treatment of migraine. JAMA. 2020;324(9):890–891. https://doi.org/10.1001/jama.2020.8493Rimegepant (Nurtec ODT) for acute treatment of migraine. JAMA. 2020;324(9):890–891. https://doi.org/10.1001/jama.2020.8493Berman G., Croop R., Kudrow D., Halverson P., Lovegren M., Thiry A.C., Conway C.M., Coric V., Lipton R.B. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache. 2020;60(8):1734–1742. https://doi.org/10.1111/head.13930Berman G., Croop R., Kudrow D., Halverson P., Lovegren M., Thiry A.C., Conway C.M., Coric V., Lipton R.B. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache. 2020;60(8):1734–1742. https://doi.org/10.1111/head.13930

The authors declare that there are no conflicts of interest present.